We are gearing up for our annual AI in Drug Discovery summit in a few days. So, for this episode, we focused on some recent AI news coverage. First, GEN senior editor Fay Lin, PhD, visited Seattle recently for some AI-focused meetings. She discusses her experiences in the Emerald City, including an exclusive in-person interview with Nobel laureate, David Baker, PhD, on what’s real and what’s hype when it comes to using AI to design proteins de novo. Then we explore new research from University of California, San Diego, that used machine learning to identify gene networks that could be targeted to reprogram cancer stem cells. We also go over some early studies that point to a possible drug candidate for colon cancer.
Listed below are links to the GEN stories referenced in this episode of Touching Base:
…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
